Overview

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

Status:
Recruiting

Trial end date:
2023-11-22

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.

Phase:

Phase 2

Details

Lead Sponsor:

Sylentis, S.A.